Administration of IV imatinib in invasively ventilated patients with COVID-19 ARDS had no significant effect on ΔEVLWi between days 1 and 4, indicating that imatinib did not reduce pulmonary edema. Imatinib did not improve clinical outcomes such as oxygenation, duration of invasive ventilation or 28-day mortality. IV imatinib was well-tolerated, with no adverse events attributed to imatinib administration.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Noortje E.
Contact Noortje E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack